EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Flunitrazepam increases the risk of lamotrigine‐induced cutaneous adverse reactions: Combined analysis of medical big data and clinical research

Hiroshi Bando iD, Mitsuhiro Goda, Masahito Nakataki iD, Keita Hirai iD, Yuki Nitta, Kei Kawada, Toshihiko Yoshioka, Masaya Kanda, Atsushi Ogawa, Chiaki Mukuta-Murakami, Kaito Tsujinaka, Koji Miyata und 10 weitere

Psychiatry and Clinical Neurosciences · 2025

DOI: 10.1111/pcn.13866 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Psychiatry and Clinical Neurosciences, 2025. Verfasst von Hiroshi Bando und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan. Hauptthemen laut MEDLINE: Lamotrigine, Anticonvulsants, Exanthema, Drug Eruptions. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Foundation for Pharmaceutical Sciences, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The concomitant use of lamotrigine and valproic acid, a uridine diphosphate (UDP)‐glucuronosyltransferase inhibitor, is a known risk factor for lamotrigine‐induced rashes, which may develop into fatal or severe cutaneous adverse reactions. No drugs other than valproic acid have been shown to increase lamotrigine concentrations in humans by inhibiting UDP‐glucuronosyltransferase. The treatment of bipolar disorder and epilepsy is often combined with other medications, which may affect the risk of rash. We aimed to identify medications that increased the risk of lamotrigine‐induced rashes using clinical data.

Methods

We used VigiBase to search for drugs associated with the increased number of reported severe cutaneous adverse reactions when combined with lamotrigine. In a retrospective study, we collected information on patients from electronic medical records and used propensity score matching to compare the incidence of lamotrigine‐induced rash with and without flunitrazepam use. Furthermore, we compared lamotrigine concentrations between patients treated with and without flunitrazepam in a prospective observational study.

Results

VigiBase analysis showed that flunitrazepam significantly increased the reporting odds ratio for lamotrigine‐related severe cutaneous adverse reactions. In the retrospective study, combining lamotrigine with flunitrazepam significantly increased the incidence of rashes. In the prospective observational study, lamotrigine with flunitrazepam significantly increased the concentration‐to‐dose ratio.

Conclusion

Flunitrazepam use may affect lamotrigine concentration and increase the risk of rash. These results have implications for the choice of sleep medication. In addition, when lamotrigine is used in combination with flunitrazepam, the lamotrigine dosing design should address lamotrigine‐induced rash management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LamotrigineAnticonvulsantsExanthemaDrug EruptionsHumansMaleFemaleRetrospective StudiesAdultMiddle AgedBipolar DisorderAgedDrug Interactions

Stichwörter der Autor:innen

UDP‐glucuronosyltransferaseflunitrazepamlamotriginemedical big datarash

Substanzen

LamotrigineAnticonvulsants

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
  • Department of Pharmacy, Tokushima University Hospital, Tokushima, Japan.
  • Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical and Heath Sciences, Hiroshima University, Hiroshima, Japan.
  • Department of Psychiatry, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
  • Department of Pharmacy, Shinshu University Hospital, Matsumoto, Japan.
  • Department of Clinical Pharmacology and Therapeutics, Shinshu University Graduate School of Medicine, Matsumoto, Japan.

ORCID-Profile: Hiroshi Bando, Masahito Nakataki, Keita Hirai, Kohei Kitagawa

Förderung

  • Research Foundation for Pharmaceutical Sciences
  • Japan Society for the Promotion of Science

Zitieren

APA

Bando, H., Goda, M., Nakataki, M., Hirai, K., Nitta, Y., Kawada, K., Yoshioka, T., Kanda, M., Ogawa, A., Mukuta-Murakami, C., Tsujinaka, K., Miyata, K., Kitagawa, K., Niimura, T., Aizawa, F., Yagi, K., Izawa-Ishizawa, Y., Chuma, M., Naito, T., …, & Ishizawa, K. (2025). Flunitrazepam increases the risk of lamotrigine‐induced cutaneous adverse reactions: Combined analysis of medical big data and clinical research. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13866

Vancouver

Bando H, Goda M, Nakataki M, Hirai K, Nitta Y, Kawada K, et al. Flunitrazepam increases the risk of lamotrigine‐induced cutaneous adverse reactions: Combined analysis of medical big data and clinical research. Psychiatry and Clinical Neurosciences. 2025. doi:10.1111/pcn.13866

BibTeX
@article{Bando2025,
  author = {Bando, Hiroshi and Goda, Mitsuhiro and Nakataki, Masahito and Hirai, Keita and Nitta, Yuki and Kawada, Kei and Yoshioka, Toshihiko and Kanda, Masaya and Ogawa, Atsushi and Mukuta-Murakami, Chiaki and Tsujinaka, Kaito and Miyata, Koji and Kitagawa, Kohei and Niimura, Takahiro and Aizawa, Fuka and Yagi, Kenta and Izawa-Ishizawa, Yuki and Chuma, Masayuki and Naito, Takafumi and Tasaki, Yoshikazu and Numata, Shusuke and Ishizawa, Keisuke},
  title = {Flunitrazepam increases the risk of lamotrigine‐induced cutaneous adverse reactions: Combined analysis of medical big data and clinical research},
  journal = {Psychiatry and Clinical Neurosciences},
  year = {2025},
  doi = {10.1111/pcn.13866}
}
Kostenlos starten →